文献速递泌尿男性生殖肿瘤

HSD3B1基因变异与非甾体CYP17A1抑制剂治疗去势抵抗性前列腺癌的疗效关联

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该观察性研究纳入90例转移性去势抵抗性前列腺癌(mCRPC)患者,在接受酮康唑治疗的人群中分析HSD3B1(1245C)胚系变异与疗效的关系。提示HSD3B1(1245C)可能是预测非甾体CYP17A1抑制剂敏感性的生物标志物。

要点

  • 该变异既是去势抵抗的预测标志物,也可能预测非甾体CYP17A1抑制剂的敏感性。

核心结论

  • HSD3B1(1245C)变异等位基因遗传是预测非甾体CYP17A1抑制剂(酮康唑)治疗敏感性的生物标志物。
  • 该发现提示可能为前列腺癌患者提供治疗分层路径。

研究设计与样本

  • 一项观察性研究,纳入1998年6月至2012年12月在加州大学旧金山分校接受酮康唑治疗的转移性去势抵抗性前列腺癌男性患者。
  • 共90例患者纳入分析(中位年龄61.5岁,四分位距55.3-67.0),其中88例有足够数据确定酮康唑治疗持续时间,81例有足够数据确定疾病进展时间。

关键数值与推荐

  • 疾病进展定义为生化进展或影像学进展,分别采用前列腺癌工作组3(PCWG3)和实体瘤疗效评价标准(RECIST)1.1版定义。
  • 采用Kaplan-Meier法估计治疗时间和疾病进展时间,采用对数秩趋势检验比较不同HSD3B1基因型间的结局。

临床怎么用

  • HSD3B1(1245C)基因分型可能用于识别更可能从非甾体CYP17A1抑制剂治疗中获益的mCRPC患者。
  • 该研究提示基于HSD3B1基因型的治疗分层路径值得进一步探索。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The HSD3B1 (1245C) germline variant encodes for a gain-of-function missense in 3β-hydroxysteroid dehydrogenase isoenzyme 1 (3βHSD1) that results in increased dihydrotestosterone synthesis from extragonadal precursors and is predictive of more rapid progression to castration-resistant prostate cancer (CRPC). OBJECTIVE: To determine whether the HSD3B1 (1245C) genotype is predictive of clinical response to extragonadal androgen ablation with nonsteroidal 17α-hydroxylase/17,20-lyase (CYP17A1) inhibition in men with metastatic CRPC. DESIGN, SETTING, AND PARTICIPANTS: An observational study of men with metastatic CRPC treated with ketoconazole between June 1998 and December 2012 was conducted at the University of California, San Francisco. EXPOSURES: Extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole among men with metastatic CRPC. MAIN OUTCOMES AND MEASURES: The primary end points of analysis were duration of ketoconazole therapy and time to disease progression stratified by HSD3B1 genotype. Disease progression was defined as either biochemical or radiographic progression, using the Prostate Cancer Working Group 3 and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 definitions, respectively. Kaplan-Meier analysis was used to estimate time on therapy and time to disease progression. A log-rank test for trend was used to compare outcomes by HSD3B1 genotype. RESULTS: A total of 90 men (median [interquartile range] age, 61.5 [55.3-67.0] years) with metastatic CRPC were included in the analysis, with sufficient data to determine duration of ketoconazole therapy and time to disease progression in 88 and 81 patients, respectively. The median duration of therapy increased with the number of inherited HSD3B1 (1245C) variant alleles: 5.0 months (95% CI, 3.4-10.4) for 0 variant alleles; 7.5 months (95% CI, 4.9-19.2) for 1; and 12.3 months (95% CI, 1.8-not reached) for 2 (overall comparison for trend, P = .01). Median progression-free survival also increased with number of HSD3B1 (1245C) variant alleles inherited: 5.4 months (95% CI, 3.7-7.5) for 0 variant alleles; 9.7 months (95% CI, 5.6-32.9) for 1; and 15.2 months (95% CI, 7.8-not reached) for 2 (overall comparison for trend, P = .03). CONCLUSIONS AND RELEVANCE: Inheritance of the HSD3B1 (1245C) variant allele, which is a predictive biomarker of resistance to castration, is also a predictive biomarker of sensitivity to extragonadal androgen ablation with a nonsteroidal CYP17A1 inhibitor. These findings signal a possible pathway of treatment stratification for patients with prostate cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Almassi N, Reichard C, Li J, et al. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA Oncol. 2018. PMID: 29049452. doi:10.1001/jamaoncol.2017.3159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。